

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) Solid dispersions comprising a poorly soluble bioactive compound dispersed in a polymer matrix, comprising more than one polymer, characterized in that a first polymer allows a homogeneous or molecular dispersion of the bioactive compound in the polymer matrix, while a second polymer has a dissolution profile associated with the creation of a micro-environment enhancing the dissolution of the bioactive compound in an aqueous environment.
2. (Original) Solid dispersions according to claim 1 characterized in that the polymer matrix comprises a polymer having a stabilizing effect on the bioactive compound in solution.
3. (Currently Amended) Solid dispersions according to claim 1 ~~claims 1 or 2~~ wherein the polymer allowing a homogeneous dispersion is PVPVA64.
4. (Currently Amended) Solid dispersions according to claim 1 ~~claims 1 to 3~~ wherein the polymer allowing enhanced dissolution of the bioactive compound in an aqueous environment is Eudragit E100.
5. (Currently Amended) Solid dispersions according to claim 1 ~~claims 1 or 2~~ wherein the polymer allowing enhanced dissolution of the bioactive compound in an aqueous environment is hydroxyl-propyl methyl cellulose.
6. (Currently Amended) Solid dispersions according to claim 1 ~~claims 1 to 2~~ wherein the polymer matrix comprises Eudragit E100 and PVPVA64.
7. (Original) Solid dispersions according to claim 6 wherein a Eudragit E100/PVPVA64 ratio varies between 70/30 and 80/20.

8. (Currently Amended) Solid dispersions according to claim 1 ~~claims 1 to 2~~ wherein the polymer matrix comprises hydroxyl-propyl methyl cellulose and PVPVA64.
9. (Currently Amended) Solid dispersions according to claim 1 ~~to 8~~ enhancing the bioavailability of an orally administered bioactive compound.
10. (Currently Amended) Solid dispersions according to claim 1 ~~claims 1 to 9~~ wherein the bioactive compound is a class II drug in the Biopharmaceutical Classification System.
11. (Currently Amended) Solid dispersions according to claim 1 ~~claims 1 to 9~~ wherein the bioactive compound is a class IV drug in the Biopharmaceutical Classification System.
- 12.. (Currently Amended) Solid dispersions according to claim 1 ~~to 11~~ wherein the aqueous environment is a gastro-intestinal fluid.
13. (Original) Solid dispersions according to claim 12 wherein the aqueous environment is a gastric fluid.
14. (Currently Amended) Solid dispersions according to claim 1 ~~any of the claims 1 to 13~~ prepared by extrusion.
15. (Currently Amended) Solid dispersion according to claim 1 ~~any of the claims 1 to 13~~ prepared by spray-drying.